Bank Of America Corp Karuna Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$161.01 - $317.85 $1.8 Million - $3.55 Million	11,167 Added 11.19%	110,962 $35.1 Million
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $23.3 Million - $31.8 Million	-132,397 Reduced 57.02%	99,795 $21.6 Million
Q1 2023 May 12, 2023	BUY	$161.33 - $204.36 $26.2 Million - $33.1 Million	162,136 Added 231.44%	232,192 $42.2 Million
Q4 2022 Feb 10, 2023	BUY	$191.53 - $236.82 $2.52 Million - $3.11 Million	13,150 Added 23.11%	70,056 $13.8 Million
Q3 2022 Nov 14, 2022	SELL	$123.79 - $277.42 $719,962 - $1.61 Million	-5,816 Reduced 9.27%	56,906 $12.8 Million
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $2.24 Million - $3.42 Million	-23,839 Reduced 27.54%	62,722 $7.93 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $4.1 Million - $5.49 Million	41,462 Added 91.94%	86,561 $11 Million
Q4 2021 Feb 08, 2022	BUY	$110.64 - $159.4 $2.26 Million - $3.26 Million	20,451 Added 82.97%	45,099 $5.91 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $13,763 - $17,118	136 Added 0.55%	24,648 $3.02 Million
Q2 2021 Sep 13, 2021	BUY	$107.45 - $135.95 $2.63 Million - $3.33 Million	24,512 New	24,512 $2.8 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.